Profile
AKAN TAK ZTS HLN TEVA VTRS
Company Name Akanda Corp. Takeda Pharmaceutical Company Limited Zoetis Inc. Haleon plc Teva Pharmaceutical Industries Limited Viatris Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $130.55K $58.03B $55.37B $49.48B $38.97B $18.16B
Employees 0.05K 49.28K 13.80K 24.56K 37.00K 32.00K
CEO Katharyn Field Christophe Weber Kristin C. Peck Brian James McNamara Richard D. Francis Scott Andrew Smith
Ratings
AKAN TAK ZTS HLN TEVA VTRS
Quant Rating Score 2 3 3 4 3 2
Quant Rating Sell Neutral Neutral Buy Neutral Sell
Trading
AKAN TAK ZTS HLN TEVA VTRS
Last Close $1.04 $14.14 $118.8 $9.68 $24.59 $10.66
High 52 $4.77 $15.52 $178.71 $11.41 $25.83 $13.37
Low 52 $1.05 $12.89 $118.8 $8.73 $12.82 $7.26
Price vs. 52 Week High -78.2 % -8.89 % -33.52 % -15.16 % -4.8 % -20.27 %
Price vs. 52 Week Low -0.95 % 9.7 % 0 % 10.88 % 91.81 % 46.83 %
Total Return
AKAN TAK ZTS HLN TEVA VTRS
1 Month Return -54.59 % 0.71 % -17.53 % 2.11 % 27.34 % 4.82 %
3 Month Return -22.39 % -6.73 % -21.96 % -0.05 % 36.16 % 0.28 %
6 Month Return -13.33 % 0.21 % -27.13 % -10.37 % 45.16 % 20.59 %
9 Month Return -40.57 % 1.73 % -24.08 % -3.1 % 48.4 % -1.84 %
YTD Return -35 % 6.8 % -27.09 % 1.47 % 11.57 % -14.38 %
1 Year Return -25.71 % 3.82 % -32.33 % 2.11 % 46.28 % -18.31 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
AKAN TAK ZTS HLN TEVA VTRS
Dividend Yield Percentage (TTM) - 3.53 % 1.62 % 1.41 % - 3.04 %
Dividend Paid and Capex Coverage Ration (TTM) -2.34 % 2.23 % 1.89 % 2.01 % 4 % 2.09 %
Dividend Per Share (TTM) - 198 % 2.03 % 0.06 % - 0.48 %
Payout Ratio (TTM) - 277.04 % 32.55 % 27.27 % - -15.34 %
Growth
AKAN TAK ZTS HLN TEVA VTRS
Asset Growth -10.47 % -0.34 % 0.76 % 3.61 % -12.97 %
Gross Profit Growth 86.98 % 9.63 % -0.19 % 10.86 % -12.66 %
Revenue Growth -61.27 % 8.33 % -0.61 % 4.32 % -4.46 %
Revenue 3 Year 40.03 % 24.31 % 19.01 % 11.71 % -16.52 %
Revenue 5 Year - 55.65 % 33.95 % -1.27 % -39.86 %
Revenue 10 Year - 113.39 % 33.95 % -34.65 % -36.45 %
EBIT Growth 90.11 % 5.67 % 13.52 % -9.52 % -109.43 %
Net Income Growth 87.31 % 6.06 % 37.46 % 185.97 % -1259.41 %
Net Income 3 Yeari Growth Per Share 96.51 % 27.46 % 4.91 % 155.65 % 49.38 %
Net Income 5 Yeari Growth Per Share 84.96 % 74.46 % 122.63 % 133.65 % -1871.56 %
Net Income 10 Yeari Growth Per Share 84.96 % 370.4 % 122.63 % -33.98 % -122.71 %
Operating Income Growth 56.4 % 10.52 % 10.52 % 1131.35 % -98.68 %
Operating Cash Flow Growth (CFG) -165.26 % 25.5 % 9.57 % -35.33 % -17.74 %
Operating 3 Year CFG 95.79 % 39.36 % 71.6 % 0.19 % -22.68 %
Operating 5 Year CFG 57.03 % 73.18 % 196.04 % 29.24 % -40.08 %
Operating 10 Year CFG 57.03 % 420.39 % 196.04 % -77.86 % -24.47 %
EPS Growth 93.55 % 7.68 % 33.33 % 184.83 % -1262.28 %
EPS Diluted Growth 93.55 % 7.89 % 33.33 % 182.76 % -1269.98 %
Book Value Per Share 156.8 % -2.96 % -1.63 % 36.19 % -8.42 %
Share Holder 3 Year Equity Growth Per Share 113.47 % 9.65 % -37.97 % -2.08 % -7.88 %
Share Holder 5 Year Equity Growth Per Share - 85.42 % -40.16 % -24.81 % -26.41 %
Share Holder 10 Year Equity Growth Per Share - 301.38 % -40.16 % -80.23 % 90.51 %
Dividend Per Share Growth - 15.33 % 49.01 % - 0.45 %
Dividend 3 Year Growth Per Share - 73.18 % -49.79 % - 45.93 %
Dividend 5 Year Growth Per Share - 163.51 % -49.97 % - -
Dividend 10 Year Growth Per Share - 493.89 % -49.97 % -100 % -
Debt Growth -91.18 % -0.16 % 6.83 % -3.86 % -22.13 %
Free Cash Flow Growth -304.67 % 41.76 % 16.27 % -43.99 % -14.98 %
Updated On 31 Dec 2024 31 Dec 2024 31 Dec 2024 31 Dec 2025 31 Dec 2024
Profitability
AKAN TAK ZTS HLN TEVA VTRS
Gross Profit Margin TTM 73.34 % 59.49 % 70.63 % 61.81 % 51.76 % 36.07 %
Return on Assets TTM -35.85 % 0.73 % 17.49 % 4.78 % 3.48 % -9.73 %
Return on Equity TTM -58.81 % 1.58 % 53.56 % 9.4 % 20.09 % -22.69 %
Return on Capital Employed TTM -104.4 % 3.59 % 26.48 % 8.34 % 11.54 % -8.43 %
Net Income Per EBT TTM 90.9 % 54.99 % 79.59 % 76.52 % 114.62 % 95.92 %
EBT Per Ebit TTM 69.63 % 44.75 % 94.2 % 88.09 % 39.3 % 149.32 %
EBIT Per Revenue TTM -978.82 % 10.28 % 37.63 % 20.49 % 18.15 % -18.25 %
Cash Flow To Debt Ratio TTM -450.87 % 23.13 % 40.09 % 12.02 % 11.62 % 13.47 %
Receivables Turnover TTM 0.36 5.89 6.1 5.14 4.68 3.94
Payables Turnover TTM 0.04 3.87 6.73 1.18 3.31 6.81
Inventory Turnover TTM - 1.29 1.12 3.72 2.63 2.2
Fixed Asset Turnover TTM 13.58 % 214.23 % 241.44 % 589.57 % 392.13 % 488.38 %
Asset Turnover TTM 5.79 % 28.97 % 61.99 % 34.62 % 42.58 % 37.25 %
Operating Cash Flow Per Share TTM -4.38 710.55 6.58 0.11 1.76 1.7
Free Cash Flow Per Share TTM -6.25 589.53 5.06 0.1 1.32 1.37
Cash Per Share TTM 626.69 % 48236.45 % 470.54 % 7.46 % 309.55 % 99.36 %
Operating Cash Flow Sales Ratio TTM -490.46 % 25.14 % 31.03 % 9.32 % 11.64 % 14.04 %
Free Cash Flow Operating Cash Flow Ratio TTM 142.76 % 82.97 % 76.82 % 90.65 % 74.99 % 80.65 %
Cash Flow Coverage Ratios TTM -450.87 % 23.13 % 40.09 % 12.02 % 11.62 % 13.47 %
Price To Free Cash Flows Ratio TTM -0.05 9.52 24.72 38.08 25.61 11.36
Price To Operating Cash Flows Ratio TTM -0.2 7.9 19.08 35.1 19.24 9.26
Price Cash Flow Ratio TTM -0.2 7.9 19.08 35.1 19.24 9.26
Income Statement (TTM)
AKAN TAK ZTS HLN TEVA VTRS
Revenue $0B $4581.55B $9.47B $11.23B $17.26B $14.74B
Gross Profit $0B $3001.33B $0B $6.95B $8.94B $5.62B
Gross Profit Ratio 24.91% 65.51% 0% 61.85% 51.79% 38.15%
EBITDA $-0B $1210.51B $0B $2.51B $3.14B $2.82B
Net Income $-0B $107.93B $2.67B $1.44B $1.41B $-0.63B
EPS Diluted -3.93 33.62 6.02 0.32 1.2 -0.53
Balance Sheet (MRQ)
AKAN TAK ZTS HLN TEVA VTRS
Long Term Debt $0B $3966.33B $0.2B $8.62B $15.56B $14.22B
Total Liabilities $0B $7312.37B $12.14B $18.09B $32.83B $22.87B
Total Equity $0B $6935.98B $3.33B $16.22B $7.91B $18.64B
Total Investments $0B $382.4B $0B $0.14B $0B $1.7B
Total Debt $0B $4515.27B $0.2B $10.1B $17.38B $14.31B
Total Assets $0.01B $14248.34B $15.47B $34.32B $40.75B $41.5B
Cash Flow Statement (TTM)
AKAN TAK ZTS HLN TEVA VTRS
Net Income $-0B $107.93B $2.67B $1.44B $1.42B $-0.63B
Inventory $0B $-34.97B $-0.2B $0.22B $0.15B $-0.72B
Dividends Paid $0B $-302.5B $-0.89B $-0.57B $0B $-0.57B
Operating Cash Flow $-0B $1057.18B $2.9B $2.3B $1.65B $2.3B
Capital Expenditure $-0B $-200.8B $-0.62B $-0.25B $-0.5B $-0.33B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 3.55
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 4.64
ALVOW Alvotech 0.3025
AMPH Amphastar Pharmaceuticals, Inc. 28.5
AMRX Amneal Pharmaceuticals, Inc. 14.82
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 77.36
APUS Apimeds Pharmaceuticals US, Inc 1.23
AQST Aquestive Therapeutics, Inc. 3.65
ASRT Assertio Holdings, Inc. 12.375
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 21.64
AYTU Aytu BioPharma, Inc. 2.13
ETFs With Exposure to AKAN
Ticker ETF Name Weight Percentage Price
MJ ETFMG Alternative Harvest ETF 0 25.25
Unlock